Results 101 to 110 of about 29,580 (292)

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report [PDF]

, 2012
Background Primary myelofibrosis is a myeloproliferative disorder characterized by bone marrow fibrosis, abnormal cytokine expression, splenomegaly and anemia.
COLOMBA, Claudia, LALICATA, Francesco, Rubino, R, Siracusa, L, TITONE LANZA DI SCALEA, Lucina, Tolomeo, M., Trizzino, M   +6 more
core   +2 more sources

Ruxolitinib attenuates secondary injury after traumatic spinal cord injury

, 2022
Haijun Li, Lei Yang, Xiaojian Cao, Zhanyang Qian, Ren-Yi Kong, Sheng Zhang, Binyu Wang, Jie Chang, Jiang Cao, Chao-Qin Wu, Ziyan Huang, Ao Duan   +11 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study

The Clinical Respiratory Journal
Introduction This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID‐19–associated cytokine storm in patients eligible for hospitalization (NCT04355793).
Jeffrey Weinstein, Nikhil Jagan, Shawnta Lorthridge‐Jackson, J. E. Hamer‐Maansson, Peg Squier   +4 more
doaj   +1 more source

Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma

Cancer Science, EarlyView.
IDO expression in stromal cells was upregulated by MM cells via the JAK–STAT1–NF‐κB–IRF1 signaling pathway. JAK inhibitor abolished IDO and IRF1 upregulation. ABSTRACT Stromal cells are an essential component of the tumor microenvironment (TME) in multiple myeloma (MM). Indoleamine 2,3‐dioxygenase 1 (IDO), an enzyme that metabolizes tryptophan (Trp) to
Toru Ebina, Masaki Ri, Yoshiaki Marumo, Tomoyuki Nakamura, Hirokazu Sasaki, Yoshiko Oshima, Takahiro Nakashima, Shinya Hagiwara, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Kazufumi Yamagata, Kohmei Kubo, Hirokazu Komatsu, Hirotake Sakuraba, Shinsuke Iida   +18 more
wiley   +1 more source

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation [PDF]

, 2020
Florian H. Heidel, Andreas Hochhaus
openalex   +1 more source

“Nomen Omen: The Myth of God Janus”

JEADV Clinical Practice, EarlyView.
Alba Guglielmo
wiley   +1 more source

Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution

Cell Proliferation, EarlyView.
We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...
Mengmeng Jiang, Haide Chen, Guoxia Wen, Yuqing Mei, Wenzhao Zhou, Bin Xu, Tingyue Zhang, Guangyan Li, Junqing Wu, Xiaoping Han, Xudong Fu, Guoji Guo, Jingjing Wang   +12 more
wiley   +1 more source

Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T‐cell lymphoma (PCAECTCL) is a rare and aggressive malignancy, with limited documented cases in pediatric patients. This report presents a unique case of a 9‐year‐old female with PCAECTCL, characterized by widespread erythematous annular lesions that exhibited an indolent clinical ...
Carrie Meng, Auris Huen, David McCall, Phyu P. Aung, Priyadharsini Nagarajan, Valentina Nardi, Carlos A. Torres‐Cabala   +6 more
wiley   +1 more source

Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives

Dermatology and Therapy
Introduction The 2021 US approval of ruxolitinib cream for treatment of atopic dermatitis (AD) in patients aged ≥ 12 years was based on the results of two pivotal phase 3 studies.
Lawrence F. Eichenfield, Jinan Liu, Simran Marwaha, James Piercy, Daniel Sturm, Peter Anderson   +5 more
doaj   +1 more source